cabozantinib (Cometriq, Cabometyx, XL184)
Jump to navigation
Jump to search
Introduction
FDA desgination as Orphan drug in Jan 2011.
Indications
- treatment of medullary thyroid carcinoma (FDA-approved 2012)[4]
- metastatic castration-resistant prostate cancer[5] (investigational)
- advanced renal cell carcinoma
- patients previously treated with VEGF inhibitor
- patients with bone metastases[6]
- advanced hepatocellular carcinoma[7]
Dosage
- oral dosing
- take on empty stomach:
- do not eat for at least 2 hours before & 1 hour after taking Cometriq
Monitor
Adverse effects
- diarrhea
- stomatitis
- hand-foot syndrome
- weight loss
- loss of appetite
- nausea
- fatigue
- oral pain
- graying or loss of hair color
- dysgeusia
- hypertension
- abdominal pain
- constipation
- abnormal liver function tests
- hypocalcemia
- hypophosphatemia
- leukopenia
- thrombocytopenia
Mechanism of action
- tyrosine kinase inhibitor
- reduces tumor growth, metastasis, & angiogenesis
More general terms
References
- ↑ FDA News Release: Nov. 29, 2012 FDA approves Cometriq to treat rare type of thyroid cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm
- ↑ Hussain M et al Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol 29: 2011 (suppl; abstr 4516) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82339
- ↑ Wikipedia: Cabozantinib http://en.wikipedia.org/wiki/Cabozantinib
- ↑ 4.0 4.1 SelleckBio.com http://www.selleckbio.com/xl184-cabozantinib-S1119.html?gclid=CJmK79zkrLUCFQfhQgodhGwAhA
- ↑ 5.0 5.1 Smith DC et al. Cabozantinib in patients with advanced prostate cancer: Results of a Phase II randomized discontinuation trial. J Clin Oncol 2013 Feb 1; 31:412 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23169517
- ↑ 6.0 6.1 Minerd J MedPage Today. January 14, 2018 Cabozantinib Bests Everolimus in RCC with Bone Metastases. Subgroup analysis of METEOR trial showed improved survival. https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/70501
Escudier B, Powles T, Motzer RJ et al Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial J Clin Oncol. 2018 Jan 8:JCO2017747352 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29309249 - ↑ 7.0 7.1 Abou-Alfa GK, Meyer T, Cheng AL et al Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379:54-63. July 5, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29972759 https://www.nejm.org/doi/full/10.1056/NEJMoa1717002